Please note, this OEL/ADE monograph also applies to fludrocortisone (CAS RN 127-31-1). Fludrocortisone acetate is a synthetic fluorinated corticosteroid with anti-inflammatory and antiallergic activities (1). It is used in conjunction with hydrocortisone as a partial replacement therapy for primary or secondary adrenocortical insufficiency in Addison's disease. It is also indicated for the treatment of salt-losing adrenogenital syndrome (3). Fludrocortisone was granted a patent in 1953 and is on the World Health Organization's List of Essential Medicines. Fludrocortisone acetate is an inactive prodrug requiring hydrolyzation by esterases or pseudoesterases in the liver and other body fluids.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Fludrocortisone Acetate, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.